

CORRECTION

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

Luca Schifanella, Susan W. Barnett, Massimiliano Bissa, Veronica Galli, Melvin N. Doster, Monica Vaccari, Georgia D. Tomaras, Xiaoying Shen, Sanjay Phogat, Ranajit Pal, David C. Montefiori, Celia C. LaBranche, Mangala Rao, Hung V. Trinh, Robyn Washington-Parks, Namal P. M. Liyanage, Giacomo Gorini, Dallas R. Brown, Frank Liang, Karin Loré, David J. Venzon, William Magnanelli, Michelle Metrinko, Josh Kramer, Matthew Breed, Galit Alter, Ruth M. Ruprecht, Genoveffa Franchini

Dr. Giacomo Gorini is not included in the author byline. He should be listed as the seventeenth author and affiliated with Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America. The contribution of this author is as follows: Methodology.

Reference

1. Schifanella L, Barnett SW, Bissa M, Galli V, Doster MN, Vaccari M, et al. (2019) ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. *PLoS Pathog* 15(12): e1008121. <https://doi.org/10.1371/journal.ppat.1008121> PMID: 31794588



OPEN ACCESS

Citation: Schifanella L, Barnett SW, Bissa M, Galli V, Doster MN, Vaccari M, et al. (2020) Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. *PLoS Pathog* 16(4): e1008531. <https://doi.org/10.1371/journal.ppat.1008531>

Published: April 28, 2020

Copyright: © 2020 Schifanella et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.